AKTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Akari Therapeutics, Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$4.40 |
| 52 Week Low | US$1.08 |
| Beta | 0.95 |
| 11 Month Change | -45.02% |
| 3 Month Change | -65.79% |
| 1 Year Change | -56.81% |
| 33 Year Change | -96.13% |
| 5 Year Change | -96.84% |
| Change since IPO | -99.74% |
Recent News & Updates
Recent updates
Akari Therapeutics GAAP EPS of $0.00
Sep 27Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely?
Sep 20
Akari Therapeutics announces positive results from pre-clinical studies of eye disease treatment
Jul 28Akari Therapeutics GAAP EPS of $0.00
Jul 20Patient completes course with Akari's stem cell transplant related complication treatment
Jul 07We're Keeping An Eye On Akari Therapeutics' (NASDAQ:AKTX) Cash Burn Rate
Dec 31Akari shares rise after FDA 'fast track' status for skin disease treatment nomacopan
Apr 28Akari Therapeutics reports FY results
Apr 21We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully
Mar 15Do Institutions Own Akari Therapeutics, Plc (NASDAQ:AKTX) Shares?
Jan 21Read This Before Selling Akari Therapeutics, Plc (NASDAQ:AKTX) Shares
Dec 17Akari Therapeutics updates trial progress; returns to profitability
Dec 11Akari Therapeutics' lead candidate shows encouraging preclinical action against inflammatory eye disease
Dec 03Shareholder Returns
| AKTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -37.5% | 2.5% | 2.2% |
| 1Y | -56.8% | 16.1% | 31.6% |
Return vs Industry: AKTX underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: AKTX underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| AKTX volatility | |
|---|---|
| AKTX Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AKTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AKTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Samir Patel | www.akaritx.com |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
Akari Therapeutics, Plc Fundamentals Summary
| AKTX fundamental statistics | |
|---|---|
| Market cap | US$15.54m |
| Earnings (TTM) | -US$20.16m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs AKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.16m |
| Earnings | -US$20.16m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -14.9% |
How did AKTX perform over the long term?
See historical performance and comparison